Arena Pharma (ARNA) Pops on More Positive Chatter

Arena Pharma (Nasdaq: ARNA) is active in pre-market action Wednesday following a 14 percent jump on Tuesday, as LifeSci Advisors issued positive commentary on the stock.

Some of the key points:

• Arena could receive a $1.2 billion one-time purchase price adjustment from Eisai based on net sales of BELVIQ;
  
• Arena will get $5 million following OEA scheduled designation;
  
• Another $60 million will be received following DEA scheduling and delivery of launch supply;
  
• Lorcaserin is entitled to 5 years of patent exclusivity under Hatch-Waxman because its a new compound;
  
• The composition is protected until 2023;
  
• Arena owns patents on lorcasein and related compounds in 69 jurisdictions; and
  
• Management sees $143 million of cash and equivalents at the end of June, which doesn't include a $20 million milestone payment.

Shares are up 4.4 percent early.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Super Micro Computer (SMCI) Falls 6%
• Indonesia Energy Corporation (INDO) squeezes higher
• ABB shares jump as 2024 profitability outlook hike offsets Q1 revenue miss